Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-09
2008-07-29
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254030, C544S180000, C544S182000, C544S238000, C544S295000, C544S350000, C544S353000, C544S355000, C544S357000, C544S360000, C544S362000, C544S363000, C544S364000, C544S367000, C544S368000, C544S391000
Reexamination Certificate
active
07405217
ABSTRACT:
This invention relates to N-aroyl cyclic amino derivatives and their use as pharmaceuticals.
REFERENCES:
patent: 6677354 (2004-01-01), Branch et al.
patent: 6943160 (2005-09-01), Branch et al.
patent: 7166608 (2007-01-01), Branch et al.
patent: 8-40999 (1996-02-01), None
patent: WO 98/57954 (1998-12-01), None
patent: WO 01/25219 (2001-04-01), None
patent: WO 01/96302 (2001-12-01), None
patent: WO 02/44172 (2002-06-01), None
patent: WO 02/089800 (2002-11-01), None
patent: WO 02/090355 (2002-11-01), None
patent: 03/032991 (2003-04-01), None
Langmead et al.Br. J. Pharmacol . ., 141: 340-346 (2004).
Porter et al.Bioorg. &Med. Chem. Lett., 11: 1907-1910 (2001).
Duxon et al.Psychopharmacology, 153: 203-209 (2001).
White et al.Peptides, 26: 2331-2338 (2005).
Ishii et al.Behav. Brain Res., 160: 11-24 (2005).
Ishii et al.Behav. Brain Res., 157: 331-341 (2005).
Ishii et al.Physiol. &Behav.; 81: 129-140 (2004).
Smith et al.Neurosci., 341: 256-258 (2003).
Haynes et al.Regulatory Peptides, 104: 153-159 (2002).
Bingham et al.Pain, 92: 81-90 (2001).
Rodgers et al.Eur. J. Neurosci., 13: 1444-1452 (2001).
Smart et al.Br. J. Pharmacol., 132: 1179-1182 (2001).
Jones et al.Psychopharmacology, 153: 210-218 (2001).
Haynes et al.Regulatory Peptides, 96: 45-51 (2000).
Rodgers et al.Neuropeptides, 36(5): 303-325 (2002).
Cai et al.Expert Opin. Ther. Patents, 16: 631-646 (2006).
Fujii et al.Chemical Abstracts, 124(No. 34333): Abstract for JP 08040999 (1996).
USPTO office action dated Oct. 10, 2007, U.S. Appl. No. 10/481,133.
Branch Clive Leslie
Johnson Christopher Norbert
Nash David John
Stemp Geoffrey
Bernhardt Emily
Kinzig Charles M.
McCarthy Mary E.
Sieburth Kathryn L.
SmithKline Beecham p.l.c.
LandOfFree
N-aroyl piperazine derivatives as orexin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-aroyl piperazine derivatives as orexin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-aroyl piperazine derivatives as orexin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3965090